Radioimmunoassay (RIA) for the determination Pancreatic Polypeptide (PP) in human serum. For research use only, not for use in diagnostic procedures.<br><br>
Pancreatic polypeptide (PP) is synthesized as an amino-terminal moiety of a precursor peptide. PP isolated from pancreas has 36 amino acid residues with an amidated C-terminal tyrosine. PP is secreted by F-cells of the islets of Langerhans. PP is localized almost entirely in the pancreas although detectable levels throughout gastrointestinal tract have been reported. PP in human plasma is reported to exist in at least four different forms: PP 1-36, PP 3-36 and two unidentified forms.<br><br>
PP is released into plasma during stimulation while eating. The physiological role of PP includes inhibition of stimulated gastric and pancreatic exocrine secretions and augmentation of insulin inhibited hepatic glucose production. These actions of PP are mediated by specific receptors. Receptor binding studies have shown that the intact C-terminal tyrosine amide is necessary for biological activity.
- Assay Description:
- 20 hour incubation (2-8°C) + 20 hours (2-8°C) + 30 min. (2-8°C) + Centrifuge 15 min. (4°C) = 40 hours, 45 min. total incubation time
- Catalog number:
- RB316RUO
- configuration:
- Reagents for 100 determinations
- controls:
- 2 controls, lyophilized
- design:
- Radioimmunoassay (RIA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- PP
- Protocol:
- Sample types:
- Human serum
- Sample volume:
- 100 µL / determination
- standards:
- 7 standards, serially diluted from 1 prepared lyophilized standard
- Standard range:
- 0 / 6.25 - 200 pmol/L
- storage:
- 2 - 8 °C
- sensitivity:
- 3 pmol/L
- Species:
- Human
- radioactivity:
- 0.75 µCi (28 kBq)
